Avinger, Inc. (AVGR) |
| 0.474 -0.124 (-20.74%) 02-14 16:00 |
| Open: | 0.5561 |
| High: | 0.6058 |
| Low: | 0.4633 |
| Volume: | 2,592,021 |
| Market Cap: | 2(M) |
| PE Ratio: | -0.05 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 10.10 |
| Resistance 1: | 9.19 |
| Pivot price: | 9.12 |
| Support 1: | 7.72 |
| Support 2: | 6.43 |
| 52w High: | 4.3689 |
| 52w Low: | 0.363 |
Avinger, Inc. is a commercial-stage medical technology firm that develops, manufactures, and markets sophisticated image-guided, catheter-based systems. These devices are utilized by physicians both domestically and internationally to treat patients suffering from Peripheral Arterial Disease (PAD). Central to Avinger's offerings is its proprietary lumivascular platform. This innovative technology integrates Optical Coherence Tomography (OCT) visualization directly into interventional catheters, providing real-time, intravascular imaging to guide doctors during PAD procedures. The company's lumivascular product suite includes the Lightbox imaging consoles, as well as the Ocelot family of catheters, which are specifically designed to help physicians penetrate complete arterial blockages. Additionally, the Pantheris is an image-guided atherectomy device enabling precise removal of plaque from affected arteries. Avinger also offers its earlier-generation Chronic Total Occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2. These employ a unique rotational spinning technique, allowing physicians to switch between passive and active modes when navigating difficult CTOs. Furthermore, the company is developing IMAGE-BTK, a specialized solution for treating PAD lesions located below-the-knee. Avinger's advanced medical devices are sold to a specialized clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists. The company was founded in 2007 and is headquartered in Redwood City, California.
| EPS | -104500000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -15.342 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -3.00 |
| Return on Assets (ttm) | 72.1 |
| Return on Equity (ttm) | -42.5 |
Thu, 24 Apr 2025
Avinger (AVGR) Stock Price, News & Analysis - Stock Titan
Thu, 20 Feb 2025
Redwood City medical device company to liquidate, pay off creditors - The Business Journals
Wed, 05 Feb 2025
Avinger Inc shareholders approve liquidation plan - Investing.com
Wed, 15 May 2024
AVGR Stock Earnings: Avinger Misses EPS, Misses Revenue for Q1 2024 - TradingView
Fri, 25 Aug 2023
Unmasking the Value Trap: A Deep Dive into Avinger Inc (AVGR) - Yahoo Finance
Wed, 10 May 2023
Avinger Reports First Quarter 2023 Results - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |